06:32 AM EDT, 06/25/2025 (MT Newswires) -- BeOne Medicines ( ONC ) said Wednesday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a new film-coated tablet formulation of its Brukinsa B-cell cancer drug for all approved indications.

The opinion is subject to a review by the European Commission, which will grant the marketing authorization for the tablet formulation in the region.

The company said it will start converting Brukinsa to tablets from capsules in regions outside China in 2025.